查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870479

犬類關節炎治療市場依治療方法、藥物類別、給藥途徑、通路、最終用戶和公司分類－2025-2032年全球預測

Canine Arthritis Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User, Company - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，犬類關節炎治療市場將成長至 36.7 億美元，複合年成長率為 8.42%。

主要市場統計數據
基準年 2024 19.2億美元
預計年份：2025年 20.8億美元
預測年份：2032年 36.7億美元
複合年成長率 (%) 8.42%

這是一份簡潔且權威的報告，闡述了正在重新定義犬類關節炎管理和相關人員優先事項的臨床、商業和看護者發展趨勢。

犬類關節炎已從單純的臨床問題演變為一項多方面的挑戰，需要臨床醫生、產品開發人員、支付者和看護者共同合作應對。儘管疼痛管理和關節保護等長期存在的臨床難題依然是重中之重，但介入措施的選擇和實施環境已發生顯著變化。獸醫專業人員需要在滿足飼主對生活品質的期望、能夠改變疾病進程的新型治療方法以及具備數位化素養、要求透明證據和便捷治療途徑的飼主群體之間尋求平衡。因此，成功的策略必須將臨床療效與支持實際治療依從性、可負擔性和慢性病管理的模式結合。

科學、消費行為和醫療服務領域發生的引人注目的變革性變化正在重新定義犬類關節炎的治療管道和商業模式。

由於科學創新、飼主期望的改變以及護理模式的演進，犬類關節炎的治療格局正在改變。在科學方面，針對單株抗體和改良型緩解疾病藥物的出現，使得人們更加關注針對潛在病理的干涉措施，而不僅僅是緩解症狀。這些進展正在開闢新的臨床途徑，並促使獸醫從業人員重新評估傳統的治療流程。此外，從遠端醫療諮詢到穿戴式活動監測器等技術的整合，使得對運動功能和治療反應的持續評估成為可能，從而進一步實現個人化護理，並有助於指導長期治療決策。

基於證據的分析，探討2025年關稅調整如何重塑犬類關節炎治療管道的採購、定價和供應韌性。

2025年關稅的累積影響正波及犬類關節炎價值鏈中的採購、定價與策略採購決策。某些藥品成分、進口成品藥和專用復健設備的關稅上調，導致到岸成本增加，並為採購計畫帶來波動。為此，製造商和經銷商正在使其供應鏈多元化，並評估各種替代方案，包括近岸外包、供應商整合以及在臨床可接受的情況下使用國內採購的組件。雖然這些調整有助於降低風險，但也需要重新分配資金，並調整與經銷商和獸醫合作夥伴的合約條款。

透過整合治療方法、藥物類別、給藥途徑、分銷管道、最終用戶和公司定位等因素，進行全面的細分分析，從而確定採用管道。

細分市場的洞察揭示了治療方案、藥理學、給藥途徑、分銷、終端用戶和企業策略如何相互交織，共同塑造護理模式。根據治療類型，市場可分為輔助療法、非藥物療法和藥物療法。輔助療法包括營養補充劑，而補充劑類別可進一步細分為軟骨素、葡萄糖胺和ω脂肪酸。非藥物療法包括針灸、雷射療法和物理療法，其中物理療法可分為水療和物理療法。另一方面，藥物療法包括緩解疾病緩解疾病藥物（DMDs），例如透明質酸和多硫酸Glico；單株抗體，例如貝地維托單抗；以及非類固醇消炎劑），例如卡洛芬、德拉考昔和美洛昔康。將藥物按類別分為骨關節炎治療藥物、單株抗體和非類固醇消炎劑，重申了臨床治療向緩解疾病和靶向生技藥品的轉變，其中透明質酸和多硫酸Glico是前一類藥物的基石，貝地貝單抗為抗體療法提供了明確的參考點，而抗發炎的非類固醇則是一種常用的美洛昔康抗發炎藥物。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 犬類幹細胞療法需求不斷成長，為關節再生修復提供了可能。
  • 將穿戴式犬類活動追蹤器整合到關節炎管理中，以改善關節炎管理。
  • 擴大老年犬隻的訂閱式關節補充品配送服務
  • 再生醫學中富血小板血漿通訊協定在緩解犬骨關節炎的進展
  • 監管政策調整旨在加速犬類關節炎新療法的核准流程
  • 提供遠距獸醫關節炎諮詢和監測的遠距遠端照護平台發展迅速
  • 實施個人化營養計劃，納入富含Omega-3的食物，以支持關節健康。
  • 透過製藥公司與獸醫技術Start-Ups之間的策略合作，創新治療方案
  • 消費者對含有新型生物活性化合物的植物來源關節補充劑興趣激增
  • 亞太市場擴張的驅動力來自寵物飼養量的增加和獸醫基礎設施的擴建。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 犬類關節炎治療市場：依治療方法

  • 輔助療法
    • 營養補充品
    • 補充
      • 軟骨素
      • 葡萄糖胺
      • 歐米伽脂肪酸
  • 非藥物療法
    • 針刺
    • 雷射療法
    • 物理治療
      • 水處理方法
      • 物理治療
  • 藥物治療
    • 緩解疾病抗風濕藥物
      • 玻尿酸
      • 多硫酸Glico聚醣
    • 單株抗體
      • 貝丁維托馬
    • 非類固醇消炎劑
      • 卡洛芬
      • 德拉考昔
      • 美洛昔康

9. 犬類關節炎治療藥物市場

  • 骨關節炎治療
    • 玻尿酸
    • 多硫酸Glico聚醣
  • 單株抗體
    • 貝丁維托馬
  • 非類固醇消炎劑
    • 卡洛芬
    • 德拉考昔
    • 美洛昔康

第10章 犬類關節炎治療市場（依給藥途徑分類）

  • 注射
    • 皮下注射
  • 口服
    • 片劑和膠囊
  • 外用藥物
    • 凝膠

第11章 犬類關節炎治療市場（依通路分類）

  • 網路藥房
    • 綜合電子商務平台
    • 獸醫的電子商務平台
  • 寵物專賣店
  • 零售藥房
  • 獸醫院藥房

第12章 犬類關節炎治療市場（依最終使用者分類）

  • 專業寵物診所
    • 復健中心
  • 動物診所
    • 綜合診所
    • 整形外科診所
  • 獸醫診所
    • 綜合獸醫院
    • 小動物醫院

第13章 犬類關節炎治療市場：依公司分類

  • Dechra
  • Elanco
  • Zoetis

第14章 犬類關節炎治療市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 犬類關節炎治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國犬類關節炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Virbac SA
    • Boehringer Ingelheim International GmbH
    • Nutramax Laboratories, Inc.
    • Colgate-Palmolive Company
    • Nestle SA
Product Code: MRR-1A1A064C0106

The Canine Arthritis Market is projected to grow by USD 3.67 billion at a CAGR of 8.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.92 billion
Estimated Year [2025] USD 2.08 billion
Forecast Year [2032] USD 3.67 billion
CAGR (%) 8.42%

A concise and authoritative introduction to the evolving clinical, commercial, and caregiver dynamics that are redefining canine arthritis management and stakeholder priorities

Canine arthritis has evolved from a narrowly clinical concern into a multifaceted challenge that demands integrated responses from clinicians, product developers, payors, and caregivers. Longstanding clinical imperatives such as pain control and joint preservation remain central, yet the context in which interventions are selected and delivered has shifted dramatically. Veterinary practitioners are balancing owner expectations for quality of life, emerging therapeutic classes that alter disease trajectory, and an increasingly digital-savvy pet owner population that seeks transparent evidence and convenient access to treatments. As a result, successful strategies must bridge clinical efficacy with real-world adherence, affordability, and service delivery models that support chronic disease management.

In parallel, research and innovation are broadening the therapeutic toolkit available to veterinarians and owners. Novel biologics and targeted therapies are being integrated alongside established pharmacological agents and a resurgent interest in nonpharmacological modalities. This plurality of options elevates the importance of comparative clinical evidence, practical guidelines for multimodal care, and communication strategies that synthesize risk-benefit profiles for diverse patient cohorts. Consequently, stakeholders must approach canine arthritis not only as a medical condition but as an ecosystem that includes preventive care, rehabilitation, nutritional strategies, and digital monitoring.

Compelling transformative shifts in science, consumer behavior, and care delivery that are redefining treatment pathways and commercial models for canine arthritis

The landscape of canine arthritis is undergoing transformative shifts driven by scientific innovation, changing client expectations, and evolving care delivery models. On the scientific front, the emergence of targeted monoclonal antibodies and refined disease modifying agents has redirected attention toward interventions that address underlying pathology rather than only symptomatic relief. These advances are catalyzing new clinical pathways and prompting veterinary clinicians to reassess long-standing treatment algorithms. Furthermore, technological integration-ranging from telehealth consultations to wearable activity monitors-enables continuous assessment of mobility and treatment response, thereby improving personalization of care and informing long-term therapeutic decisions.

Concurrently, client expectations are reshaping market dynamics. Pet owners increasingly evaluate treatment options through the lens of long-term outcomes, safety profiles, and convenience. This shift elevates the role of complementary therapies and rehabilitation services as acceptable components of multimodal regimens. Finally, commercial and regulatory pressures are prompting manufacturers and distributors to rethink supply chain resilience and pricing strategies. As stakeholders adapt, the industry is moving toward integrated care models that combine pharmacological therapies, nonpharmacological interventions, and owner-centered support to optimize outcomes across diverse canine populations.

An evidence-oriented analysis of how United States tariff adjustments in twenty twenty five are reshaping procurement, pricing, and supply resilience across canine arthritis care pathways

The cumulative impact of tariffs implemented in the United States in twenty twenty five reverberates across procurement, pricing, and strategic sourcing decisions within the canine arthritis value chain. Tariff escalations on select pharmaceutical ingredients, finished imported formulations, and specialized rehabilitation equipment have increased landed costs and introduced volatility in procurement planning. In response, manufacturers and distributors have intensified scrutiny of supply chain diversification, evaluating alternatives such as nearshoring, vendor consolidation, and substitution with domestically sourced components where clinically acceptable. These adaptations, while mitigating exposure, have required capital reallocation and adjustments to contractual terms with distributors and veterinary partners.

Clinicians and practice managers have observed indirect consequences in the clinic, including tighter inventory management and incremental cost pass-through for certain imported therapeutics or advanced rehabilitation devices. At the same time, the tariff environment has accentuated the competitive advantage of companies with vertically integrated production or established domestic manufacturing footprints, as these players can buffer price increases and maintain supply continuity. Importantly, the policy-induced cost pressures have also stimulated innovation in product formulation and delivery, with stakeholders exploring low-cost manufacturing techniques, reformulation to reduce reliance on affected inputs, and extended-duration therapeutics that reduce frequency of procurement and improve adherence.

Comprehensive segmentation insights integrating treatment modalities, drug classes, administration routes, distribution channels, end users, and company positioning to reveal adoption pathways

Segment-specific insights reveal how treatment choices, pharmacology, administration routes, distribution, end users, and company strategies intersect to shape care patterns. Based on treatment type, the market divides into complementary therapies, nonpharmacological therapies, and pharmacological therapies, where complementary therapies encompass nutraceuticals and supplements and the supplements category further includes chondroitin, glucosamine, and omega fatty acids; nonpharmacological therapies encompass acupuncture, laser therapy, and physical therapy with physical therapy branching into hydrotherapy and physiotherapy, while pharmacological therapies include disease modifying agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs, the disease modifying agents further characterized by hyaluronic acid and polysulfated glycosaminoglycan, monoclonal antibodies represented by bedinvetmab, and nonsteroidal anti inflammatory drugs exemplified by carprofen, deracoxib, and meloxicam. Based on drug class, the breakdown into disease modifying osteoarthritic agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs reiterates the clinical pivot toward disease modification and targeted biologics, with hyaluronic acid and polysulfated glycosaminoglycan anchoring the former category and bedinvetmab providing a clear reference point for antibody therapies while carprofen, deracoxib, and meloxicam represent commonly used NSAIDs.

Based on route of administration, injectable, oral, and topical formats frame clinical decision making, with injectable options often delivered subcutaneously and oral therapies typically administered in tablet or capsule form while topical preparations are commonly available in gel formulations. Based on distribution channel, online pharmacies, pet specialty stores, retail pharmacies, and veterinary hospital pharmacies define access pathways, with online channels segmented between general e commerce platforms and specialized veterinary e commerce platforms that influence adherence and price transparency. Based on end user, specialty pet clinics, veterinary clinics, and veterinary hospitals reflect where care is delivered; specialty pet clinics frequently include rehabilitation centers, veterinary clinics can be divided into general practice and orthopedic clinics, and veterinary hospitals range from multispecialty facilities to small animal hospitals. Based on company, market activity concentrates among established players such as Dechra, Elanco, and Zoetis, each shaping product development, distribution strategies, and clinical education in distinct ways. Taken together, these segmentation frames illuminate where clinical innovation, commercial investment, and practical adoption are converging and where gaps remain for targeted evidence generation and service optimization.

Key regional dynamics and market entry considerations across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, access, and commercialization strategies

Regional dynamics materially influence research priorities, regulatory pathways, and commercial approaches across the Americas, Europe Middle East and Africa, and Asia Pacific, each presenting distinct epidemiological profiles and care delivery ecosystems. In the Americas, high pet ownership rates and advanced veterinary practice infrastructure favor rapid uptake of novel therapeutics and integrated care models, while direct-to-consumer digital channels and robust specialty clinic networks support adoption of multimodal regimens and rehabilitation services. Conversely, Europe Middle East and Africa exhibit heterogeneous regulatory frameworks and variable access to high-cost biologics, which creates differentiated market corridors where domestically produced formulations and cost-effective complementary therapies often find traction.

In the Asia Pacific region, rapid modernization of veterinary services, growing pet-owning middle classes, and expanding online retail ecosystems are accelerating demand for both established pharmaceuticals and innovative modalities, yet distribution complexity and regulatory variance require localized commercialization strategies. Across regions, differences in veterinary workforce capacity, reimbursement norms, and owner willingness to invest in chronic disease management drive divergent adoption curves for advanced therapeutics and supportive services. As a result, regional strategies must be calibrated to local regulatory realities, channel structures, and owner expectations to unlock sustainable growth and meaningful clinical impact.

Key company profiles and strategic positioning that explain how scale, specialization, and R&D focus drive competitive advantage in the canine arthritis ecosystem

Company-level positioning demonstrates how scale, pipeline composition, and commercial capabilities determine competitive advantage in canine arthritis. Dechra is recognized for its focus on specialty veterinary pharmaceuticals and customer-centric distribution strategies that reinforce relationships with clinical decision makers. Elanco leverages a broad portfolio and global reach to support integrated product rollouts and collaborative research partnerships with academic and clinical institutions. Zoetis combines deep R&D capabilities with extensive field sales forces and clinician education programs that drive clinical uptake and post-launch evidence generation. Together, these companies exemplify different strategic archetypes: specialized specialty-focused execution, diversified portfolio leverage, and scale-driven clinical influence.

Beyond these leading players, a range of smaller innovators and contract manufacturers contribute to category evolution by introducing novel formulations, digital monitoring tools, and localized manufacturing partnerships. Strategic collaborations among incumbents and niche technology providers are increasingly important for translating biologic advances into scalable clinical solutions. For industry stakeholders, identifying the role each company plays in the distribution ecosystem and clinical education landscape informs partnership strategies, competitive benchmarking, and tactical investment decisions.

Practical and prioritized recommendations for industry leaders to align clinical evidence, integrated care pathways, and supply chain resilience for sustained competitive advantage

Actionable recommendations for leaders focus on aligning clinical value, commercial feasibility, and operational resilience to capture long term opportunity. First, prioritize evidence generation that addresses comparative effectiveness, long term safety, and real world outcomes for multimodal regimens, ensuring that clinical trials and postmarket studies are designed to produce practice-relevant endpoints. Second, invest in integrated care pathways that combine pharmacological, nonpharmacological, and supportive services, and pair these programs with digital tools that simplify owner engagement and adherence monitoring. Third, fortify supply chain resilience by diversifying sourcing, evaluating nearshoring options, and developing contingency plans for imported inputs to mitigate tariff and import volatility.

In addition, cultivate deep clinician partnerships through continuing education, practical toolkits for multimodal therapy implementation, and co developed case registries that accelerate learning. Align commercial strategies with regional realities by tailoring pricing, channel mix, and regulatory engagement to local market dynamics. Finally, assess strategic collaborations with smaller innovators and service providers to accelerate time to market for differentiated offerings while leveraging incumbents' distribution and clinician education capabilities. Implementing these recommendations will strengthen competitive positioning and improve care outcomes across diverse clinical and commercial contexts.

A transparent research methodology combining primary clinician interviews, secondary clinical and regulatory review, and analytical triangulation to support actionable insights

The research underpinning this executive summary combines qualitative and quantitative approaches to ensure robust, multiperspective analysis. Primary research included structured interviews with veterinary clinicians, practice managers, and industry executives to capture clinical practice patterns, adoption drivers, and commercial priorities. Secondary research reviewed peer reviewed clinical literature, regulatory guidance, public company disclosures, and product monographs to corroborate findings and contextualize technological trajectories. Comparative analyses were performed to map therapeutic mechanisms, administration routes, and distribution channel economics against observed adoption trends.

Analytical methods encompassed thematic synthesis of interview data, cross validation of product and company claims with regulatory filings and clinical trial registries, and scenario analysis to evaluate the operational impacts of supply chain and policy shifts. Throughout the process, emphasis was placed on triangulation between clinician experience, commercial intelligence, and documented clinical evidence to reduce bias and strengthen practical relevance. The methodology supports actionable insights by focusing on implementation barriers, evidence gaps, and strategic levers that stakeholders can operationalize within their organizations.

A forward-looking conclusion synthesizing clinical advances, operational challenges, and strategic imperatives that must be reconciled to improve canine arthritis outcomes

In conclusion, canine arthritis represents a dynamic area where scientific advances, client expectations, and commercial realities intersect to create both complexity and opportunity. The maturation of disease modifying agents and targeted biologics offers the potential to shift treatment paradigms toward longer term joint health, while nonpharmacological and complementary therapies are increasingly recognized as essential components of multimodal care. Regional and policy variables, such as tariff changes and distribution channel evolution, introduce operational challenges that demand proactive supply chain and pricing strategies. Success in this environment will require stakeholders to invest in rigorous evidence generation, clinician engagement, and pragmatic commercialization models that prioritize real world outcomes and owner adherence.

Moving forward, organizations that combine clinical credibility with operational agility and collaborative partnerships will be best positioned to deliver meaningful improvements in canine mobility and quality of life. By aligning research priorities with practical implementation pathways and regional market nuances, stakeholders can convert scientific promise into scalable clinical and commercial outcomes that address both current needs and future opportunities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for canine stem cell therapies offering regenerative joint repair
  • 5.2. Integration of wearable canine activity monitors to enhance arthritis management outcomes
  • 5.3. Expansion of subscription based joint supplement delivery services targeting senior dogs
  • 5.4. Advancements in canine regenerative platelet rich plasma protocols for osteoarthritis relief
  • 5.5. Regulatory updates accelerating approval pathways for novel canine arthritis therapeutics
  • 5.6. Growth of telemedicine platforms providing remote veterinary arthritis consultations and monitoring
  • 5.7. Adoption of personalized nutrition plans incorporating omega 3 enriched diets for joint support
  • 5.8. Strategic partnerships between pharmaceutical companies and veterinary tech startups to innovate treatment options
  • 5.9. Surge in consumer interest for plant based joint supplements formulated with novel bioactive compounds
  • 5.10. Market expansion in Asia Pacific driven by increasing pet ownership and growing veterinary infrastructure

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Arthritis Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Nutraceuticals
    • 8.1.2. Supplements
      • 8.1.2.1. Chondroitin
      • 8.1.2.2. Glucosamine
      • 8.1.2.3. Omega Fatty Acids
  • 8.2. Non Pharmacological Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Laser Therapy
    • 8.2.3. Physical Therapy
      • 8.2.3.1. Hydrotherapy
      • 8.2.3.2. Physiotherapy
  • 8.3. Pharmacological Therapies
    • 8.3.1. Disease Modifying Agents
      • 8.3.1.1. Hyaluronic Acid
      • 8.3.1.2. Polysulfated Glycosaminoglycan
    • 8.3.2. Monoclonal Antibodies
      • 8.3.2.1. Bedinvetmab
    • 8.3.3. Non Steroidal Anti Inflammatory Drugs
      • 8.3.3.1. Carprofen
      • 8.3.3.2. Deracoxib
      • 8.3.3.3. Meloxicam

9. Canine Arthritis Market, by Drug Class

  • 9.1. Disease Modifying Osteoarthritic Agents
    • 9.1.1. Hyaluronic Acid
    • 9.1.2. Polysulfated Glycosaminoglycan
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Bedinvetmab
  • 9.3. Non Steroidal Anti Inflammatory Drugs
    • 9.3.1. Carprofen
    • 9.3.2. Deracoxib
    • 9.3.3. Meloxicam

10. Canine Arthritis Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Tablet Capsule
  • 10.3. Topical
    • 10.3.1. Gel

11. Canine Arthritis Market, by Distribution Channel

  • 11.1. Online Pharmacies
    • 11.1.1. General E Commerce Platforms
    • 11.1.2. Vet E Commerce Platforms
  • 11.2. Pet Specialty Stores
  • 11.3. Retail Pharmacies
  • 11.4. Veterinary Hospital Pharmacies

12. Canine Arthritis Market, by End User

  • 12.1. Specialty Pet Clinics
    • 12.1.1. Rehabilitation Centers
  • 12.2. Veterinary Clinics
    • 12.2.1. General Practice Clinics
    • 12.2.2. Orthopedic Clinics
  • 12.3. Veterinary Hospitals
    • 12.3.1. Multispecialty Hospitals
    • 12.3.2. Small Animal Hospitals

13. Canine Arthritis Market, by Company

  • 13.1. Dechra
  • 13.2. Elanco
  • 13.3. Zoetis

14. Canine Arthritis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Canine Arthritis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Canine Arthritis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Elanco Animal Health Incorporated
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Dechra Pharmaceuticals PLC
    • 17.3.5. Vetoquinol SA
    • 17.3.6. Virbac SA
    • 17.3.7. Boehringer Ingelheim International GmbH
    • 17.3.8. Nutramax Laboratories, Inc.
    • 17.3.9. Colgate-Palmolive Company
    • 17.3.10. Nestle S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPANY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CANINE ARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANINE ARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANINE ARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)

TABLE 318.